References
- 1. CAO M, LEITE BN, FERREIRO T, CALVO M, FERNANDEZ C, ALONSO A, et al., Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury. Am J Nephrol 2018; 48: p. 225–233.
- 2. NORIS M and REMUZZI G, Atypical hemolytic–uremic syndrome. N Engl J Med 2009; 361: p. 1676–1687.
- 3. CAMPISTOL JM, ARIAS M, ARICETA G, BLASCO M, ESPINOSA L, ESPINOSA M, et al., An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015; 35: p. 421–447.
- 4. KATO H, MIYAKAWA Y, HIDAKA Y, INOUE N, ITO S, KAGAMI S, et al., Safety and effectiveness of Eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019; 23: p. 65–75.
- 5. RAINA R, GREWAL MK, RADHAKRISHNAN Y, TATINENI V, DECOY M, BURKE LL, et al., Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019; 12: p. 183.
- 6. KRISHNAPPA V, GUPTA M, ELRIFAI M, MOFTAKHAR B, ENSLEY MJ, VACHHARAJANI TJ, et al., Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial 2018; 22: p. 178–188.
- 7. LEE H, KANG E, KANG HG, KIM YH, KIM JS, KIM H-J, et al., Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020; 35: p. 25–40.
- 8. KHWAJA A, KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012; 120: p. c179–c184.
- 9. CAMPISTOL JM, ARIAS M, ARICETA G, BLASCO M, ESPINOSA M, GRINYÓ JM, et al., An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia.2015;35(5):421–447
- 10. FREMEAUX-BACCHI V, FAKHOURI F, GARNIER A, BIENAIMÉ F, DRAGON-DUREY M-A, NGO S, et al., Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8: p. 554–562.
- 11. NORIS M, CAPRIOLI J, BRESIN E, MOSSALI C, PIANETTI G, GAMBA S, et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5: p. 1844–1859.
- 12. JOKIRANTA TS, HUS and atypical HUS. Blood, T 2017; 129: p. 2847–2856.
- 13. LEGENDRE CM, LICHT C, MUUS P, GREENBAUM L, BABU S, BEDROSIAN C, et al., Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med. 2013; 368: p. 2169–2181.
- 14. GOODSHIP TH, COOK HT, FAKHOURI F, FERVENZA FC, FRÉMEAUX-BACCHI V, KAVANAGH D, et al., Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 2017; 91: p. 539–551.
- 15. OSBORNE AJ, BRENO M, BORSA NG, BU F, FRÉMEAUX-BACCHI V, GALE DP, et al., Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Immunol 2018; 200: p. 2464–2478.
- 16. CAVERO T, RABASCO C, LÓPEZ A, ROMÁN E, ÁVILA A, SEVILLANO Á, et al., Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017; 32: p. 466–474.
- 17. MERRILL SA, BRITTINGHAM ZD, YUAN X, MOLITERNO AR, SPERATI CJ, and BRODSKY RA, Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 2017; 130: p. 368–372.
- 18. FAKHOURI F, FILA M, PROVÔT F, DELMAS Y, BARBET C, CHÂTELET V, et al., Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017; 12: p. 50–59.
- 19. ARDISSINO G, POSSENTI I, TEL F, TESTA S, SALARDI S, and LADISA V, Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015; 66: p. 172–173.
- 20. OLSON SR, LU E, SULPIZIO E, SHATZEL JJ, RUEDA JF, and DELOUGHERY TG, When to stop Eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018; 48: p. 96–107.
- 21. FREMEAUX-BACCHI V, MOULTON EA, KAVANAGH D, DRAGON-DUREY M-A, BLOUIN J, CAUDY A, et al., Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2006; 17: p. 2017–2025.
- 22. WIJNSMA KL, DUINEVELD C, VOLOKHINA EB, VAN DEN HEUVEL LP, VAN DE KAR NC, and WETZELS JF, Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 2018; 33: p. 635–645.